U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07747480) titled 'A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis' on July 31.
Brief Summary: This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.
Study Start Date: Aug. 10
Study Type: INTERVENTIONAL
Condition:
Colitis, Ulcerative
Intervention:
BIOLOGICAL: Aletekitug
Aletekitug will be administered.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: GlaxoSmithKline
Published by HT Digital Co...